Literature DB >> 22024842

Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux.

David O Francis1, Marion Goutte, James C Slaughter, C Gaelyn Garrett, David Hagaman, Michael D Holzman, Michael F Vaezi.   

Abstract

OBJECTIVES/HYPOTHESIS: Fundoplication is considered in patients with refractory extraesophageal reflux symptoms. However, postoperative symptom resolution is inconsistent. This analysis investigates which presenting symptoms and preoperative objective parameters predict postoperative symptom improvement. STUDY
DESIGN: Retrospective cohort study.
METHODS: A total of 237 patients referred for extraesophageal reflux symptoms refractory to medical therapy underwent esophageal function testing. Fundoplication was performed in 27 patients with objective evidence of gastroesophageal reflux disease. Symptomatic improvement was assessed at postoperative intervals. Logistic regression determined which symptoms and objective parameters predicted improvement of the presenting extraesophageal reflux symptom.
RESULTS: Overall, 59% of patients reported at least partial improvement of their presenting extraesophageal symptom after fundoplication. Predictors of symptomatic improvement were the presence of heartburn with or without regurgitation concomitant to their primary presenting symptom (odds ratio [OR], 6.6; 95% confidence interval [CI], 0.97-44.9; P = .05) and pH < 4 more than 12% of a 24-hour period (OR, 10.5; 95% CI, 1.36-81.1; P = .02). Probability of postoperative extraesophageal reflux symptom improvement was 90% if both conditions were present.
CONCLUSIONS: Both heartburn with or without regurgitation and esophageal pH < 4 more than 12% of a 24-hour period predicted postfundoplication resolution of the presenting extraesophageal reflux symptom.
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22024842     DOI: 10.1002/lary.21897

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  33 in total

1.  Clinical outcomes of gastroesophageal reflux disease-related chronic cough following antireflux fundoplication.

Authors:  Tamara Díaz Vico; Enrique F Elli
Journal:  Esophagus       Date:  2019-10-15       Impact factor: 4.230

Review 2.  Oropharyngeal Reflux Monitoring and Atypical Gastroesophageal Reflux Disease.

Authors:  Dhyanesh A Patel; Ali H Harb; Michael F Vaezi
Journal:  Curr Gastroenterol Rep       Date:  2016-03

3.  Laryngopharyngeal Reflux and Functional Laryngeal Disorder: Perspective and Common Practice of the General Gastroenterologist.

Authors:  Dhyanesh A Patel; Michael Blanco; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-09

Review 4.  Surgical Treatment of Extraesophageal Manifestations of Gastroesophageal Reflux Disease.

Authors:  Feroze Sidwa; Alessandra L Moore; Elaine Alligood; P Marco Fisichella
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

Review 5.  Extra-esophageal manifestations of GERD: who responds to GERD therapy?

Authors:  Rishi D Naik; Michael F Vaezi
Journal:  Curr Gastroenterol Rep       Date:  2013-04

6.  Chronic Cough and Gastroesophageal Reflux Disease.

Authors:  David O Francis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-01

Review 7.  Esophageal Impedance Monitoring: Clinical Pearls and Pitfalls.

Authors:  Karthik Ravi; David A Katzka
Journal:  Am J Gastroenterol       Date:  2016-06-21       Impact factor: 10.864

8.  Combined pH-impedance testing for reflux: current state of play and future challenges.

Authors:  Santosh Sanagapalli; Rami Sweis
Journal:  Frontline Gastroenterol       Date:  2017-04-21

9.  Insight Into the Relationship Between Gastroesophageal Reflux Disease and Asthma.

Authors:  Fehmi Ates; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

10.  New developments in extraesophageal reflux disease.

Authors:  Elif Saritas Yuksel; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.